Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Brasofensine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 12/20 | 0.58 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brasofensine SCHEMBL20390950 | 0.94 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| Brasofensine SCHEMBL14762214 | 0.94 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| Brasofensine SCHEMBL539079 | 0.94 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| Brasofensine SCHEMBL1649206 | 0.94 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| Brasofensine SCHEMBL20390946 | 0.94 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| Brasofensine SCHEMBL29426326 | 0.90 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7455410 | 0.85 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7460089 | 0.85 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3671497 | 0.83 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL2996397 | 0.83 | SLC6A3 (0.57) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257541-B1 | POLYPHARMACOPHORIC AGENTS | MOLECULAR INSIGHT PHARM INC (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070129440-A1 | Polypharmacophoric agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-7141573-B2 | Polypharmacophoric agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1257541-A2 | POLYPHARMACOPHORIC AGENTS | Biostream Therapeutics (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020042357-A1 | Polypharmacophoric agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001051474-A2 | POLYPHARMACOPHORIC AGENTS | BIOSTREAM THERAPEUTICS, INC. (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042357-A1 | Polypharmacophoric agents | COMT, SLC6A3, HTR3C | SLC6A3 2/4885SLC6A2 26/4885SLC6A4 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.